Cargando…

A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway

BACKGROUND: We have previously demonstrated that ginsenoside compound K can attenuate the formation of atherosclerotic lesions. Therefore, ginsenoside compound K has potential for atherosclerosis therapy. How to improve the druggability and enhance the antiatherosclerotic activity of ginsenoside com...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yan, Ran, Xiaodong, Liu, Hongmei, Luo, Mingming, Qin, Yiyu, Yan, Jinqiong, Li, Xiaohui, Jia, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273626/
https://www.ncbi.nlm.nih.gov/pubmed/37322486
http://dx.doi.org/10.1186/s13020-023-00758-0
_version_ 1785059692836290560
author Huang, Yan
Ran, Xiaodong
Liu, Hongmei
Luo, Mingming
Qin, Yiyu
Yan, Jinqiong
Li, Xiaohui
Jia, Yi
author_facet Huang, Yan
Ran, Xiaodong
Liu, Hongmei
Luo, Mingming
Qin, Yiyu
Yan, Jinqiong
Li, Xiaohui
Jia, Yi
author_sort Huang, Yan
collection PubMed
description BACKGROUND: We have previously demonstrated that ginsenoside compound K can attenuate the formation of atherosclerotic lesions. Therefore, ginsenoside compound K has potential for atherosclerosis therapy. How to improve the druggability and enhance the antiatherosclerotic activity of ginsenoside compound K are the core problems in the prevention and treatment of atherosclerosis. CKN is a ginsenoside compound K derivative that was previously reported to have excellent antiatherosclerotic activity in vitro, and we have applied for international patents for it. METHODS: Male C57BL/6 ApoE(−/−) mice were fed a high-fat and high-choline diet to induce atherosclerosis and were subjected to in vivo studies. In vitro, the CCK-8 method was applied to evaluate cytotoxicity in macrophages. Foam cells were utilized, and cellular lipid determination was performed for in vitro studies. The area of atherosclerotic plaque and fatty infiltration of the liver were measured by image analysis. Serum lipid and liver function were determined by a seralyzer. Immunofluorescence and western blot analysis were conducted to explore the alterations in the expression levels of lipid efflux-related proteins. Molecular docking, reporter gene experiments and cellular thermal shift assays were used to verify the interaction between CKN and LXRα. RESULTS: After confirming the therapeutic effects of CKN, molecular docking, reporter gene experiments and cellular thermal shift assays were used to predict and investigate the antiatherosclerotic mechanisms of CKN. CKN exhibited the greatest potency, with a 60.9% and 48.1% reduction in en face atherosclerotic lesions on the thoracic aorta and brachiocephalic trunk, reduced plasma lipid levels and decreased foam cell levels in the vascular plaque content in HHD-fed ApoE(−/−) mice. Moreover, CKN in the present study may exert its antiatherosclerotic effects through activated ABCA1 by promoting LXRα nuclear translocation and reducing the adverse effects of LXRα activation. CONCLUSIONS: Our results revealed that CKN prevented the formation of atherosclerosis in ApoE(−/−) mice by activating the LXRα pathway. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00758-0.
format Online
Article
Text
id pubmed-10273626
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102736262023-06-17 A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway Huang, Yan Ran, Xiaodong Liu, Hongmei Luo, Mingming Qin, Yiyu Yan, Jinqiong Li, Xiaohui Jia, Yi Chin Med Research BACKGROUND: We have previously demonstrated that ginsenoside compound K can attenuate the formation of atherosclerotic lesions. Therefore, ginsenoside compound K has potential for atherosclerosis therapy. How to improve the druggability and enhance the antiatherosclerotic activity of ginsenoside compound K are the core problems in the prevention and treatment of atherosclerosis. CKN is a ginsenoside compound K derivative that was previously reported to have excellent antiatherosclerotic activity in vitro, and we have applied for international patents for it. METHODS: Male C57BL/6 ApoE(−/−) mice were fed a high-fat and high-choline diet to induce atherosclerosis and were subjected to in vivo studies. In vitro, the CCK-8 method was applied to evaluate cytotoxicity in macrophages. Foam cells were utilized, and cellular lipid determination was performed for in vitro studies. The area of atherosclerotic plaque and fatty infiltration of the liver were measured by image analysis. Serum lipid and liver function were determined by a seralyzer. Immunofluorescence and western blot analysis were conducted to explore the alterations in the expression levels of lipid efflux-related proteins. Molecular docking, reporter gene experiments and cellular thermal shift assays were used to verify the interaction between CKN and LXRα. RESULTS: After confirming the therapeutic effects of CKN, molecular docking, reporter gene experiments and cellular thermal shift assays were used to predict and investigate the antiatherosclerotic mechanisms of CKN. CKN exhibited the greatest potency, with a 60.9% and 48.1% reduction in en face atherosclerotic lesions on the thoracic aorta and brachiocephalic trunk, reduced plasma lipid levels and decreased foam cell levels in the vascular plaque content in HHD-fed ApoE(−/−) mice. Moreover, CKN in the present study may exert its antiatherosclerotic effects through activated ABCA1 by promoting LXRα nuclear translocation and reducing the adverse effects of LXRα activation. CONCLUSIONS: Our results revealed that CKN prevented the formation of atherosclerosis in ApoE(−/−) mice by activating the LXRα pathway. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00758-0. BioMed Central 2023-06-15 /pmc/articles/PMC10273626/ /pubmed/37322486 http://dx.doi.org/10.1186/s13020-023-00758-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Yan
Ran, Xiaodong
Liu, Hongmei
Luo, Mingming
Qin, Yiyu
Yan, Jinqiong
Li, Xiaohui
Jia, Yi
A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
title A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
title_full A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
title_fullStr A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
title_full_unstemmed A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
title_short A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
title_sort novel dammarane triterpenoid alleviates atherosclerosis by activating the lxrα pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273626/
https://www.ncbi.nlm.nih.gov/pubmed/37322486
http://dx.doi.org/10.1186/s13020-023-00758-0
work_keys_str_mv AT huangyan anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT ranxiaodong anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT liuhongmei anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT luomingming anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT qinyiyu anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT yanjinqiong anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT lixiaohui anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT jiayi anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT huangyan noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT ranxiaodong noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT liuhongmei noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT luomingming noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT qinyiyu noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT yanjinqiong noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT lixiaohui noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway
AT jiayi noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway